Florida Cancer Specialists and Research Institute (FCS) shared Sarah Cannon Research Institute’s post on LinkedIn, adding:
“We are proud to see the contributions of Florida Cancer Specialists and Research Institute recognized as part of the impactful research presented at ESMO 2026.
Patients enrolled through FCS clinical trial sites helped support studies featured in the Presidential Symposium, including TroFuse-005, which demonstrated a significant improvement in overall survival for patients with advanced endometrial cancer.
These advancements underscore the critical role community oncology practices play in bringing innovative therapies and research opportunities closer to patients.
Thank you to our physicians, research teams and patients whose dedication continues to drive progress in cancer care.”
Quoting Sarah Cannon Research Institute’s post:
“Last month, oncology leaders gathered in Madrid for ESMO 2026, where emerging data and new research continue to shape conversations across the field.
Looking back on the meeting gives us a chance to recognize what SCRI investigators contributed, including more than 85 abstracts and presentations and three Phase III studies featured in the Presidential Symposium.
Each of those three studies appeared simultaneously in The Lancet or The New England Journal of Medicine.
- TroFuse-005 showed that sacituzumab tirumotecan extended median overall survival in advanced endometrial cancer from 12.1 to 19.0 months compared with chemotherapy, with patients enrolled at sites including Florida Cancer Specialists and Research Institute.
- DeLLphi-305 found that adding tarlatamab to durvalumab maintenance extended median overall survival in extensive-stage small cell lung cancer from 12.7 to 21.1 months.
- KRAScendo-1 showed divarasib extended median progression-free survival in previously treated KRAS G12C-mutated non-small cell lung cancer to 9.8 months, compared with 5.7 months for sotorasib or adagrasib.
Bo Wang, MD, of Willamette Valley Cancer Institute and Research Center, contributed to both lung cancer studies.
Results like these depend on investigators, research teams and patients in community practices across the country. We’re grateful to everyone who made them possible.
Read the full ESMO 2026 recap.”
You can also read: TroFuse-005 at ESMO 2026: Sacituzumab Tirumotecan Significantly Improves Overall Survival in Advanced Endometrial Cancer
